BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30649385)

  • 1. The Genomic Landscape of Mucinous Breast Cancer.
    Pareja F; Lee JY; Brown DN; Piscuoglio S; Gularte-Mérida R; Selenica P; Da Cruz Paula A; Arunachalam S; Kumar R; Geyer FC; Silveira C; da Silva EM; Li A; Marchiò C; Ng CKY; Mariani O; Fuhrmann L; Wen HY; Norton L; Vincent-Salomon A; Brogi E; Reis-Filho JS; Weigelt B
    J Natl Cancer Inst; 2019 Jul; 111(7):737-741. PubMed ID: 30649385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
    Pareja F; Selenica P; Brown DN; Sebastiao APM; da Silva EM; Da Cruz Paula A; Del A; Fu L; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
    Histopathology; 2019 Jul; 75(1):139-145. PubMed ID: 30843622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
    Pareja F; Vahdatinia M; Marchio C; Lee SSK; Da Cruz Paula A; Derakhshan F; da Silva EM; Selenica P; Dopeso H; Chandarlapaty S; Wen HY; Vincent-Salomon A; Brogi E; Weigelt B; Reis-Filho JS
    J Clin Pathol; 2022 Jan; 75(1):10-17. PubMed ID: 33148628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
    Lacroix-Triki M; Suarez PH; MacKay A; Lambros MB; Natrajan R; Savage K; Geyer FC; Weigelt B; Ashworth A; Reis-Filho JS
    J Pathol; 2010 Nov; 222(3):282-98. PubMed ID: 20815046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.
    Nguyen B; Veys I; Leduc S; Bareche Y; Majjaj S; Brown DN; Boeckx B; Lambrechts D; Sotiriou C; Larsimont D; Desmedt C
    J Natl Cancer Inst; 2019 Jul; 111(7):742-746. PubMed ID: 30789657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Genomic Landscape of Male Breast Cancers.
    Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
    Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Kyker-Snowman K; Erlanger Avigdor B; Nasim M; Cimino-Mathews A; Wheelan SJ; Argani P; Park BH
    Breast Cancer Res Treat; 2018 Jul; 170(2):425-430. PubMed ID: 29541976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.
    Sun P; Zhong Z; Lu Q; Li M; Chao X; Chen D; Hu W; Luo R; He J
    Mod Pathol; 2020 Oct; 33(10):1945-1960. PubMed ID: 32358590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A microscopic landscape of the invasive breast cancer genome.
    Ping Z; Xia Y; Shen T; Parekh V; Siegal GP; Eltoum IE; He J; Chen D; Deng M; Xi R; Shen D
    Sci Rep; 2016 Jun; 6():27545. PubMed ID: 27283966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.